Learn Why Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Purchased Cerus Corp Stake?

February 14, 2018 - By Ellis Scott

 Learn Why Julian Baker And Felix Baker's Baker Bros. Advisors Lp Purchased Cerus Corp Stake?

Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.02, from 1.3 in 2017Q2. It is positive, as 9 investors sold Cerus Corporation shares while 22 reduced holdings. 11 funds opened positions while 30 raised stakes. 57.26 million shares or 0.28% less from 57.42 million shares in 2017Q2 were reported.

Ubs Asset Mgmt Americas invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Deutsche Bank Ag holds 0% or 1.64 million shares. Price T Rowe Associate Incorporated Md accumulated 112,000 shares. The New York-based Bnp Paribas Arbitrage has invested 0% in Cerus Corporation (NASDAQ:CERS). Balyasny Asset Mngmt Lc invested in 22,800 shares. Tiaa Cref Invest Ltd Liability reported 356,854 shares. Marathon Management holds 0.04% in Cerus Corporation (NASDAQ:CERS) or 36,000 shares. State Board Of Administration Of Florida Retirement accumulated 36,846 shares or 0% of the stock. Goldman Sachs Gp owns 103,716 shares. Sg Americas Securities Lc holds 0% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 20,933 shares. Amalgamated Bancorporation invested in 0% or 12,928 shares. Citadel Advsrs Ltd owns 933,089 shares. Glenmede Trust Na reported 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). 8.34M were reported by Blackrock. Jpmorgan Chase reported 0% of its portfolio in Cerus Corporation (NASDAQ:CERS).

The New Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Holding in Cerus Corp

Baker Bros. Advisors Lp reported SC 13G/A form with the SEC for Cerus Corp. Access it here: 000114420418007909. As reported by Julian Baker And Felix Baker’s Baker Bros. Advisors Lp, the filler owns 667% or 9,765,073 shares of the Health Care–company.

Cerus Corp stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s positive view for Cerus Corp. For a hedge fund managing $8.20 billion in assets and having 25+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s portfolio is in the sector.

Cerus Corp Institutional Sentiment

Filings show 114 investors own Cerus Corp. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 7774655. 73422043 were owned by these investors. 19 funds opened new Cerus Corp stakes, 42 increased positions. There were 14 that closed positions and 32 reduced them.

Birchview Capital Lp is an investor bullish on Cerus Corp, owning 83000 shares as of Q3 2015 for 0.23% of its portfolio. Justin John Ferayorni Tamarack Capital Management Llc owns 900000 shares or 0.49% of its portfolio. NY Baker Bros Advisors Lp have 0.57% of its portfolio for 13553275 shares. Further, Lesa Sroufe & Co reported stake worth 2.14% of its portfolio. The CT Bolton Lp owns 88900 shares. Cerus Corp is 0.06% of its portfolio.

Business Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

SEC Form 13G.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on March, 6. They expect $-0.12 earnings per share, up 7.69 % or $0.01 from last year’s $-0.13 per share. After $-0.12 actual earnings per share reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

The stock increased 3.90% or $0.15 during the last trading session, reaching $4. About 1.07M shares traded. Cerus Corporation (NASDAQ:CERS) has declined 40.83% since February 14, 2017 and is downtrending. It has underperformed by 57.53% the S&P500.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $497.66 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 5 analysts covering Cerus (NASDAQ:CERS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cerus has $8 highest and $4.0 lowest target. $5.50’s average target is 37.50% above currents $4 stock price. Cerus had 10 analyst reports since August 11, 2015 according to SRatingsIntel. As per Thursday, November 30, the company rating was maintained by Robert W. Baird. Wedbush downgraded the stock to “Neutral” rating in Thursday, December 17 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, June 7. Zacks downgraded the stock to “Buy” rating in Tuesday, August 11 report. Robert W. Baird maintained Cerus Corporation (NASDAQ:CERS) rating on Monday, October 30. Robert W. Baird has “Buy” rating and $4.0 target. Robert W. Baird maintained Cerus Corporation (NASDAQ:CERS) rating on Wednesday, January 24. Robert W. Baird has “Buy” rating and $6.0 target. On Monday, January 8 the stock rating was maintained by Cantor Fitzgerald with “Buy”. BTIG Research maintained the stock with “Buy” rating in Friday, May 26 report. BTIG Research maintained the shares of CERS in report on Wednesday, August 19 with “Buy” rating. As per Thursday, October 5, the company rating was maintained by Cowen & Co.

More news for Cerus Corporation (NASDAQ:CERS) were recently published by: Fool.com, which released: “Here’s Why Cerus Corporation Stock Popped Today” on January 24, 2018. Businesswire.com‘s article titled: “Cerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study …” and published on January 23, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: